Menu
← Oncology Approval Tracker
FDA DECISION ·
Padcev + Keytruda
enfortumab vedotin-ejfv + pembrolizumab · Astellas Pharma / Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with locally advanced or metastatic urothelial cancer. This decision broadened the combination beyond the population previously eligible under accelerated approval.
LAMPGEN ANALYSIS
Why it matters
The combination moved into a wider first-line population, including patients who could receive cisplatin.
What research teams should watch
Use the applicable action date to distinguish the April cisplatin-ineligible cohort from this broader approval.
PRIMARY RECORDS